Mizuho Securities Remains Bullish on Mallinckrodt (MNK) Following Strong 4Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Mallinckrodt plc Reports Fiscal 2016 Fourth Quarter and Full-Year Results
November 29, 2016 6:00 AM ESTCHESTERFIELD, United Kingdom, Nov. 29, 2016 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today reported results for the fourth quarter fiscal 20161. Unless otherwise noted, all comparisons of fiscal 2016 fourth quarter or full fiscal year performance are to the comparable periods of fiscal 2015. As announced in the Aug. 24, 2016 press release, Mallinckrodt now presents its nuclear imaging business as a discontinued operation for all periods.
Net sales... More



